Data Demonstrates Complete Response (CR) Rate of 57 Percent in Patients with LG UTUC All Evaluated Patients in CR Remain Disease Free at Six Months Rolling Submission of New Drug Application (NDA) Initiated in December 2018 NEW YORK --(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd.

Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology NEW YORK --(BUSINESS WIRE)--Jan. 3, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field